Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerʼs disease - Egan, M F; Mukai, Y; Voss, T; Kost, J; Stone, J; Furtek, C; Mahoney, E; Cummings, J L; Tariot, P N; Aisen, P S; Vellas, B; Lines, C; Michelson, D (Alzheimers Res Ther, 2019)